Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)
Public ClinicalTrials.gov record NCT07089784. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of MK-2828 in Participants With Type 2 Diabetes
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to learn about the safety and if people tolerate a study medicine called MK-2828. The study will also measure what happens to MK-2828 in the body of a person with type 2 diabetes (T2D) over time (pharmacokinetic or PK study), and how it affects the amount of high-sensitivity C-reactive protein (hsCRP) in a person's blood.
Study identification
- NCT ID
- NCT07089784
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 46 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 24 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 21, 2025
- Primary completion
- May 3, 2026
- Completion
- May 3, 2026
- Last update posted
- May 21, 2026
2025 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ProSciento Inc. ( Site 0004) | Chula Vista | California | 91911 | — |
| California Clinical Trials Medical Group managed by PAREXEL ( Site 0008) | Glendale | California | 91206 | — |
| Velocity Clinical Research, Hallandale Beach ( Site 0010) | Hallandale | Florida | 33009 | — |
| Jacksonville Center for Clinical Research ( Site 0002) | Jacksonville | Florida | 32216 | — |
| Advanced Pharma CR, LLC ( Site 0001) | Miami | Florida | 33147 | — |
| QPS Miami Research Associates ( Site 0005) | South Miami | Florida | 33143 | — |
| AMR Lexington ( Site 0012) | Lexington | Kentucky | 40509 | — |
| Alliance for Multispecialty Research, LLC ( Site 0013) | Kansas City | Missouri | 64114 | — |
| Bio-Kinetic Clinical Applications, LLC dba QPS-MO ( Site 0009) | Springfield | Missouri | 65802 | — |
| AMR Clinical ( Site 0003) | Knoxville | Tennessee | 37920 | — |
| ICON Early Phase Services ( Site 0006) | San Antonio | Texas | 78209 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07089784, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 21, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07089784 live on ClinicalTrials.gov.